Myriad Pharmaceuticals, Inc.
305 Chipeta Way
Salt Lake City, Utah 84108
March 10, 2010
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jennifer Riegel, Esq.
| RE: | Myriad Pharmaceuticals, Inc. |
Registration Statement on Form S-4 (File No. 333-164890)
Acceleration Request
Dear Ms. Riegel:
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, Myriad Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement be made effective at 12:00 p.m. Eastern Time, on Friday, March 12, 2010, or as soon as practicable thereafter.
In connection with the foregoing request, the Company hereby acknowledges that:
| • | should the Commission or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the filing; |
| • | the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| • | the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
The Company respectfully requests that it be notified of such effectiveness by a telephone call to Brian P. Keane, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. at (617) 348-3093 and that such effectiveness also be confirmed in writing. Any questions regarding this request may be addressed to Mr. Keane.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Very truly yours,
Myriad Pharmaceuticals, Inc.
/s/ Adrian N. Hobden
By: Adrian N. Hobden
Its: President and Chief Executive Officer